Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| K24DA057873 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
The study will use social media to recruit a diverse sample of people who self-report injecting drugs, assessing the feasibility of online assessments and participants' ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and will be mailed HIV testing kits that they will self-administer and mail to a central laboratory. Investigators will track completion of questionnaires and whether at-home self-administered HIV tests were completed and sent to the laboratory.
In the past decade, injection drug use (IDU) has been linked to rural and urban HIV outbreaks, increased hepatitis C virus (HCV) transmission, and skyrocketing overdose rates in the US. Internet-based mail delivery public health programs mail naloxone or other HIV prevention supplies where allowed by law. Recruiting people who inject drugs (PWID) for research has traditionally been done in person, and the feasibility of collecting data from those who are recruited via the internet is unknown. Thus, the study's objectives are to: (1) recruit a representative sample of people who inject drugs for internet-based HIV prevention research; and (2) test the feasibility of at-home HIV testing for people who inject drugs.
This study will use social media to recruit 500 PWID. Investigators will assess the feasibility of online assessments and PWID's ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and investigators will mail participants HIV testing kits that they will self-administer and mail to a central laboratory. No other supplies will be mailed to participants.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| At-home self-administered HIV testing | Experimental | All participants will be mailed at-home self-administered HIV testing kits |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mail delivery of at-home self-administered HIV tests | Diagnostic Test | Investigators will mail participants an OraSure HIV-1 Oral Specimen Collection Device. The kit will include a self-addressed and stamped envelope with the collection device. Participants will follow enclosed directions to collect oral-fluid samples and mail them to the study laboratory for analysis. Envelopes and samples will only be marked with a bar code and not with any other personal identifiers (e.g., name or address). |
| Measure | Description | Time Frame |
|---|---|---|
| HIV test completion | This outcome will be the percentage of enrolled participants that have valid HIV testing results. The numerator will be the number of HIV test kits collected properly and sent to the laboratory for testing successfully. The denominator will be the total number of enrolled participants. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Screening feasibility | This outcome will measure the percentage of potential participants who complete enrollment. The numerator will be the number of participants that complete screening questionnaires and provide informed consent. The denominator will be the total number of potential participants that click on study advertisement or link to the study. | Baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guillermo Sanchez-Fat, MD | Contact | 347-514-1513 | guillermo.sanchezfat@einsteinmed.edu |
| Name | Affiliation | Role |
|---|---|---|
| Aaron Fox | Montefiore Medical Center/Albert Einstein College of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Montefiore Medical Center | Recruiting | The Bronx | New York | 10467 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33710493 | Background | Hayes BT, Favaro J, Davis CS, Gonsalves GS, Beletsky L, Vlahov D, Heimer R, Fox AD. Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. J Urban Health. 2021 Aug;98(4):532-537. doi: 10.1007/s11524-021-00534-1. Epub 2021 Mar 12. No abstract available. | |
| 34619446 | Background | Hayes BT, Favaro J, Coello D, Behrends CN, Jakubowski A, Fox AD. Participants of a mail delivery syringe services program are underserved by other safe sources for sterile injection supplies. Int J Drug Policy. 2022 Jan;99:103474. doi: 10.1016/j.drugpo.2021.103474. Epub 2021 Oct 5. |
Not provided
Not provided
Data collected on injection drug use could include self-disclosure of illegal activity. Participant information will be kept confidential to protect privacy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Feasibility of study procedures | This outcome will be the percentage of enrolled participants that complete baseline questionnaires and mail in HIV testing kits to the laboratory. The numerator will be the number of HIV test kits received at the laboratory and the denominator will be the total number of enrolled participants. | 12 months |
| 32915328 | Background | D'Angelo AB, Morrison CA, Lopez-Rios J, MacCrate CJ, Pantalone DW, Stief M, Grov C. Experiences Receiving HIV-Positive Results by Phone: Acceptability and Implications for Clinical and Behavioral Research. AIDS Behav. 2021 Mar;25(3):709-720. doi: 10.1007/s10461-020-03027-5. |